Co-expression of IDO1 and PD-L1 in lung squamous cell carcinoma: Potential targets of novel combination therapy

Recently, many combination therapies involving an immune checkpoint inhibitor targeting the programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) pathway and another treatment option such as chemotherapy, radiation therapy, and various immunotherapy agents have been explored to improve the response rate and clinical outcomes in various solid tumors including non-small cell lung cancer (NSCLC) [1 –8]. Especially, combination therapy with an indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor and a PD-1/PD-L1 inhibitor is expected to be a novel and effective treatment option and is currently attracting a lot of attention.
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research

Related Links:

Authors: Zhu K, Chen L, He C, Lang Y, Kong X, Qu C, Xu S Abstract Introduction. Preoperative detection of pleural invasion in lung cancer patients is key to curative surgical treatment. We tried to predict pleural invasion in non-small-cell lung cancer patients with
Source: Disease Markers - Category: Laboratory Medicine Tags: Dis Markers Source Type: research
Discussion and Review of the Literature. Oncologist. 2020 Feb 24;: Authors: Grecea M, Marabelle A, Ammari S, Massard C, Champiat S Abstract A breakthrough in oncology over the last 5 years, immunotherapy has proved its salutary effects in a wide range of solid tumors. The targeting of the programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) pathway can restore a competent antitumor T-cell response by addressing key tumor immune evasion mechanisms. This novel mechanism of action is associated with new patterns of responses that were not observed with conventional treatments s...
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Oncologist Source Type: research
CONCLUSIONS: We strictly determined prognostic genes of NSCLC, which would contribute to its carcinogenesis investigation and therapeutic methods improvement. PMID: 32083573 [PubMed - as supplied by publisher]
Source: Cancer Biomarkers - Category: Cancer & Oncology Tags: Cancer Biomark Source Type: research
Abstract The purpose of the present study was to evaluate the clinical profiles and treatment outcomes of patients with lung cancer admitted to the Medical Psychiatric Unit (MPU), which is built for patients with physical and severe psychiatric disorders. All medical records of patients with lung cancer admitted to the MPU of Tachikawa hospital were reviewed. The clinical outcomes of these patients were retrospectively evaluated between January 2010 and December 2016. A total of 24 patients in the MPU were histologically or cytologically diagnosed with primary lung cancer. Of these, 20 patients had schizophrenia, ...
Source: Clinical Lung Cancer - Category: Cancer & Oncology Authors: Tags: Mol Clin Oncol Source Type: research
In this study, we evaluated the efficacy of anlotinib as third ‐ or further‐line treatment for patient with different histological types of NSCLC. In the ALTER0303 trial, 336 patients had the histological subtype of adenocarcinoma (ACC), 86 patients had the histological subtype of squamous cell carcinoma (SCC), and 15 patients had another subtype. Our findi ngs suggest that anlotinib significantly improves PFS and OS in ACC patients and has a tendency to prolong survival in SCC patients. AbstractBackgroundAnlotinib showed significant survival benefits in advanced non ‐small cell lung cancer (NSCLC) patients as a thir...
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: ORIGINAL RESEARCH Source Type: research
Conclusions: These results suggest that FGFR1 amplification occurs more frequently in SCC and in Asians. FGFR1 amplification may be a potential new therapeutic target for specific patients and lung cancer subtypes. PMID: 32051701 [PubMed]
Source: Archives of Medical Science - Category: General Medicine Tags: Arch Med Sci Source Type: research
Conditions:   Pancreatic Ductal Adenocarcinoma;   Non-small Cell Lung Cancer;   Squamous Cell Carcinoma of Head and Neck Interventions:   Biological: Durvalumab;   Biological: Oleclumab Sponsors:   University Health Network, Toronto;   AstraZeneca Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Authors: Wang X, Ren X, Liu W, Chen X, Wei J, Gong Z, Yan Y, Xu Z Abstract Non‑small cell lung cancer (NSCLC) is prevalent worldwide. Lung squamous cell carcinoma (LUSC) is one of the main subtypes of NSCLC yet, currently, few biomarkers are available for the diagnosis of LUSC. The present study aimed to investigate the expression and role of adenosine deaminase RNA specific B1 (ADARB1) in lung squamous cell carcinoma (LUSC). Integrative bioinformatics analysis was used to identify the effects of ADARB1 expression on the occurrence and prognosis of LUSC. The expression of ADARB1 was further examined by immunohist...
Source: Molecular Medicine Reports - Category: Molecular Biology Tags: Mol Med Rep Source Type: research
Accounting for 18% of all cancer-related deaths, lung cancer is the leading cause of cancer-related mortality worldwide[1]. It comprises two main subtypes, small-cell and non-small-cell lung cancer (NSCLC), the latter representing over 80% of lung cancers. NSCLC is further divided by histologic subtypes. Adenocarcinoma (ADC) (60%) and squamous cell carcinoma (SCC) (35%) are the most common, each with distinct genomic profiles [2,3]. Until recently, the prognosis of advanced NSCLC was dire due to limited therapeutic options, with a 5-year survival rate under 5%[4].
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Tags: Hot Topic Source Type: research
Publication date: Available online 3 February 2020Source: Inorganic Chemistry CommunicationsAuthor(s): Burak Ay, İlyas Gönül, Burcu Saygıdeğer Demir, Yasemin Saygıdeğer, İbrahim KaniAbstractHerein, we describe the synthesis and characterization of two novel nickel complexes, [Ni(L1)2] (1) and [Ni(L2)2(CH3COO)].9H2O(CH3COOH) (2), containing (E)-2-(((2-(diethylamino)ethyl)imino)methyl)-6-ethoxyphenol (HL1) and (E)-2-(((2-(dimethylamino)ethyl)imino)methyl)-6-methoxyphenol (HL2) ligands. Complexes have been synthesized under conventional methods and characterized by elemental analysis, FT-IR, ICP-OES, TGA, and ...
Source: Inorganic Chemistry Communications - Category: Chemistry Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Immunotherapy | Lung Cancer | Non-Small Cell Lung Cancer | Radiation Therapy | Skin Cancer | Squamous Cell Carcinoma